Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25136859 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Alvita Vilkeviciute und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu St. 2, LT-50161 Kaunas, Lithuania. Hauptthemen laut MEDLINE: Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor A, Interleukin-10, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research Council of Lithuania under the initiative of Researcher Group Projects., The Research Council of Lithuania under the initiative of Researcher Group Projects.
Abstract (Originalsprache)
Age-related macular degeneration (AMD) is a progressive neurodegenerative condition leading to vision loss and eventual blindness, with exudative AMD posing a heightened risk due to choroidal neovascularization and localized edema. Therapies targeting the VEGF pathway aim to address this mechanism for treatment effectiveness. Our study aimed to evaluate associations between specific genetic variants (RAD51B rs8017304, rs2588809; TRIB1 rs6987702, rs4351379; COL8A1 rs13095226; COL10A1 rs1064583; IL-9 rs1859430, rs2069870, rs11741137, rs2069885, rs2069884; IL-10 rs1800871, rs1800872, rs1800896; VEGFA rs1570360, rs699947, rs3025033, rs2146323) and the response to anti-VEGF treatment for exudative AMD. We enrolled 119 patients with exudative AMD categorized as responders or non-responders based on their response to anti-VEGF treatment. Statistical analysis revealed that RAD51B rs8017304 heterozygous and homozygous minor allele carriers had increased CMT before treatment compared to wild-type genotype carriers (p = 0.004). Additionally, TRIB1 rs4351379 heterozygous and homozygous minor allele carriers exhibited a greater decrease in central macular thickness (CMT) after 6 months of treatment than wild-type genotype carriers (p = 0.030). IL-9 rs1859430, rs2069870, and rs2069884 heterozygous and homozygous minor allele carriers had worse BCVA before treatment than wild-type genotype carriers (p = 0.018, p = 0.012, p = 0.041, respectively). Conversely, IL-9 rs2069885 heterozygous and homozygous minor allele carriers showed greater improvement in BCVA after 6 months compared to wild-type genotype carriers (p = 0.032). Furthermore, VEGFA rs699947 heterozygous and homozygous minor allele carriers had better BCVA before treatment and after 3 and 6 months of treatment than wild-type genotype carriers (p = 0.003, p = 0.022, respectively), with these carriers also exhibiting higher CMT after 6 months of anti-VEGF treatment (p = 0.032). Not all results remained statistically significant under this stringent correction for multiple comparisons. The comparisons of the serum concentrations of IL-10, VEGF-A, and VEGF-R2/KDR between non-responders and responders did not yield statistically significant differences. Our study identified significant associations between genetic variants, including RAD51B rs8017304, TRIB1 rs4351379, IL-9 rs1859430, rs2069870, rs2069884, rs2069885, and VEGFA rs699947, and parameters related to the efficacy of exudative AMD treatment, such as BCVA and CMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.
- Medical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus St. 9, LT-44307 Kaunas, Lithuania.
- Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.
ORCID-Profile: Alvita Vilkeviciute
Förderung
- The Research Council of Lithuania under the initiative of Researcher Group Projects.
- The Research Council of Lithuania under the initiative of Researcher Group Projects
Zitieren
APA
Vilkeviciute, A., Cebatoriene, D., Kriauciuniene, L., Zaliuniene, D., & Liutkeviciene, R. (2024). Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25136859
Vancouver
Vilkeviciute A, Cebatoriene D, Kriauciuniene L, Zaliuniene D, Liutkeviciene R. Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25136859
BibTeX
@article{Vilkeviciute2024,
author = {Vilkeviciute, Alvita and Cebatoriene, Dzastina and Kriauciuniene, Loresa and Zaliuniene, Dalia and Liutkeviciene, Rasa},
title = {Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25136859}
}
EUVIMED